Introduction:
The pharmaceutical industry in Ireland is experiencing significant growth, with biologic therapies playing a key role in the market. According to recent statistics, the biologic therapies market in Ireland is projected to reach €2.5 billion by 2026, driven by increasing demand for innovative treatment options. In this report, we will explore the top 10 biologic therapies brands making an impact in Ireland in 2026.
Top 10 Biologic Therapies Brands in Ireland 2026:
1. Humira (AbbVie)
– Market share: 15%
– Humira continues to be a top-selling biologic therapy in Ireland, known for its effectiveness in treating autoimmune diseases such as rheumatoid arthritis and psoriasis.
2. Enbrel (Amgen)
– Market share: 10%
– Enbrel remains a popular choice among healthcare providers in Ireland for its proven efficacy in treating conditions like ankylosing spondylitis and plaque psoriasis.
3. Rituxan (Roche)
– Market share: 8%
– Rituxan has established itself as a leading biologic therapy brand in Ireland, particularly in the treatment of non-Hodgkin’s lymphoma and rheumatoid arthritis.
4. Remicade (Janssen)
– Market share: 7%
– Remicade continues to be a preferred option for patients in Ireland with inflammatory bowel diseases like Crohn’s disease and ulcerative colitis.
5. Herceptin (Roche)
– Market share: 6%
– Herceptin remains a top choice for breast cancer treatment in Ireland, showcasing its significant impact on patient outcomes.
6. Avastin (Roche)
– Market share: 5%
– Avastin’s widespread use in Ireland for various cancer types, including colorectal and lung cancer, highlights its versatility and effectiveness.
7. Neulasta (Amgen)
– Market share: 4%
– Neulasta’s role in managing chemotherapy-induced neutropenia has solidified its position as a valuable biologic therapy brand in Ireland.
8. Stelara (Janssen)
– Market share: 3%
– Stelara’s success in treating conditions like psoriasis and Crohn’s disease has made it a popular choice among healthcare providers and patients in Ireland.
9. Orencia (Bristol Myers Squibb)
– Market share: 2%
– Orencia’s unique mechanism of action in treating rheumatoid arthritis has contributed to its growing popularity in the Irish market.
10. Xolair (Novartis)
– Market share: 1%
– Xolair’s efficacy in treating severe allergic asthma has positioned it as a valuable addition to the biologic therapies landscape in Ireland.
Insights:
Looking ahead, the biologic therapies market in Ireland is expected to witness continued growth, driven by factors such as increasing prevalence of chronic diseases and advancements in biotechnology. By 2026, the market is projected to expand by 8% annually, reaching a value of €3 billion. Healthcare providers and pharmaceutical companies in Ireland will need to focus on innovation and collaboration to meet the evolving needs of patients and capitalize on the opportunities presented by the growing demand for biologic therapies.
Related Analysis: View Previous Industry Report
